Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Cash from Operations: 2014-2025

Historic Cash from Operations for ImmunityBio (IBRX) over the last 12 years, with Sep 2025 value amounting to -$68.9 million.

  • ImmunityBio's Cash from Operations rose 30.24% to -$68.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$319.7 million, marking a year-over-year increase of 24.12%. This contributed to the annual value of -$391.2 million for FY2024, which is 6.67% down from last year.
  • According to the latest figures from Q3 2025, ImmunityBio's Cash from Operations is -$68.9 million, which was up 13.65% from -$79.8 million recorded in Q2 2025.
  • In the past 5 years, ImmunityBio's Cash from Operations ranged from a high of -$60.5 million in Q1 2021 and a low of -$115.3 million during Q4 2023.
  • In the last 3 years, ImmunityBio's Cash from Operations had a median value of -$85.9 million in 2025 and averaged -$90.2 million.
  • Per our database at Business Quant, ImmunityBio's Cash from Operations plummeted by 96.58% in 2021 and then spiked by 30.24% in 2025.
  • Over the past 5 years, ImmunityBio's Cash from Operations (Quarterly) stood at -$71.6 million in 2021, then dropped by 26.64% to -$90.7 million in 2022, then declined by 27.05% to -$115.3 million in 2023, then increased by 26.14% to -$85.1 million in 2024, then skyrocketed by 30.24% to -$68.9 million in 2025.
  • Its last three reported values are -$68.9 million in Q3 2025, -$79.8 million for Q2 2025, and -$85.9 million during Q1 2025.